logo
logo
Vericel Corporation

Vericel Corporation

NASDAQ•VCEL
CEO: Mr. Dominick C. Colangelo Esq.
セクター: Healthcare
業種: Biotechnology
上場日: 1997-02-04
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
連絡先情報
64 Sidney Street, Cambridge, MA, 02139, United States
617-588-5555
vcel.com
時価総額
$1.86B
PER (TTM)
142.1
19.5
配当利回り
--
52週高値
$58.77
52週安値
$29.24
52週レンジ
26%
順位56Top 81.7%
2.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$67.50M+16.57%
直近4四半期の推移

EPS

$0.10-643.48%
直近4四半期の推移

フリーCF

$19.45M-52.51%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Total Revenue Growth Total revenue reached $183.34M for nine months, marking a 13.3% increase over prior year period driven by MACI volume.
MACI Sales Accelerating MACI implants, kits, and instruments revenue grew 20.5% to $155.42M for nine months ended September 30, 2025.
Net Loss Significantly Reduced Nine-month net loss narrowed 28.8% to $6.73M, driven by gross profit improvement and expense control measures.
Cash Position Solidified Cash, equivalents, and restricted cash totaled $100.40M as of September 30, 2025, providing strong liquidity for operations.

リスク要因

Epicel Revenue Declining Epicel sales dropped 21.7% to $23.95M for nine months, indicating ongoing market pressure for the skin replacement product.
NexoBrid Supply Chain NexoBrid manufacturing relies on MediWound facilities in Israel, posing potential disruption risk from Middle East conflicts.
Regulatory Uncertainty Risks FDA review timelines and potential policy changes create uncertainty impacting product approvals and commercialization timelines.
Credit Risk Concentration Concentration of credit risk exists in cash deposits exceeding FDIC limits and marketable debt securities holdings.

見通し

MACI Ankle Trial Launch Initiate MACI Ankle clinical trial in 2025, targeting significant long-term growth driver expansion for the product.
Sustained Operational Funding Expect current cash, investments, and borrowing capacity sufficient to support current operations for at least 12 months.
MACI Arthro Adoption Drive Expanded target surgeon base to 7,000 to drive adoption of MACI Arthro arthroscopic delivery method.
New Tax Disclosure Adoption Evaluating impact of ASU 2023-09 regarding detailed income tax disclosure requirements expected to be adopted in 2025.

同業比較

売上高 (TTM)

Harmony Biosciences Holdings, Inc.HRMY
$825.94M
+21.1%
Immunocore Holdings plcIMCR
$379.59M
+27.8%
MannKind CorporationMNKD
$313.79M
+17.4%

粗利益率 (最新四半期)

Viridian Therapeutics, Inc.VRDN
100.0%
+0.0pp
AbCellera Biologics Inc.ABCL
100.0%
+588.5pp
Immunocore Holdings plcIMCR
99.5%
+0.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EWTX$3.18B-20.2-30.9%0.7%
VRDN$2.30B-7.7-52.6%4.1%
MESO$2.16B-21.6-19.3%16.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-3.6%
横ばい
4四半期純利益CAGR
-36.5%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月26日
|
EPS:$0.45
|
売上高:$92.66M
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $67.50M+16.6%
    |
    EPS: $0.10-643.5%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月31日|
    売上高: $63.24M+20.1%
    |
    EPS: $-0.01-88.6%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $52.60M+2.6%
    |
    EPS: $-0.23+186.8%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $237.22M+20.1%
    |
    EPS: $0.21+413.9%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $57.91M+27.0%
    |
    EPS: $-0.02-76.0%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $52.66M+14.7%
    |
    EPS: $-0.10-12.5%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $51.28M+25.0%
    |
    EPS: $-0.08-38.3%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月29日|
    売上高: $197.52M+20.2%
    |
    EPS: $-0.07+80.9%
    予想を下回る